Toll-like receptors and NOD-like receptors in rheumatic diseases

Arthritis Research and Therapy

Volumn 11, Issue 5, 2009, Pages

  McCormack, William J ^a   Parker, Andrew E ^a   O'Neill, Luke A ^b  

^a Dublin Molecular Medicine Centre   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPYRIN; INTERLEUKIN 1BETA; MYELOID DIFFERENTIATION FACTOR 88; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 2; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN;

ANKYLOSING SPONDYLITIS; CYTOKINE PRODUCTION; GOUT; HUMAN; INFECTION; LYME DISEASE; NONHUMAN; OSTEOARTHRITIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; PSEUDOGOUT; PSORIATIC ARTHRITIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE INJURY; ANIMAL; IMMUNOLOGY; METABOLISM;

ANIMALS; HUMANS; NOD SIGNALING ADAPTOR PROTEINS; RHEUMATIC DISEASES; TOLL-LIKE RECEPTORS;

EID: 75649087425     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2729     Document Type: Review

References (74)

1. O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 2008, 226:10-18. 10.1111/j.1600-065X.2008.00701.x, 19161412.
2. Jin MS, Kim SE, Heo JY, Lee ME, Kim HM, Paik SG, Lee H, Lee JO. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 2007, 130:1071-1082. 10.1016/j.cell.2007.09.008, 17889651.
3. Kim HM, Park BS, Kim JI, Kim SE, Lee J, Oh SC, Enkhbayar P, Matsushima N, Lee H, Yoo OJ, Lee JO. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 2007, 130:906-917. 10.1016/j.cell.2007.08.002, 17803912.
4. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, Walsh EE, Freeman MW, Golenbock DT, Anderson LJ, Finberg RW. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000, 1:398-401. 10.1038/80833, 11062499.
5. Awomoyi AA, Rallabhandi P, Pollin TI, Lorenz E, Sztein MB, Boukhvalova MS, Hemming VG, Blanco JC, Vogel SN. Association of TLR4 polymorphisms with symptomatic respiratory syncytial virus infection in high-risk infants and young children. J Immunol 2007, 179:3171-3177.
6. Kenny EF, O'Neill LA. Signalling adaptors used by Toll-like receptors: an update. Cytokine 2008, 43:342-349. 10.1016/j.cyto.2008.07.010, 18706831.
7. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009, 27:229-265. 10.1146/annurev.immunol.021908.132715, 19302040.
8. Verma D, Lerm M, Blomgran Julinder R, Eriksson P, Soderkvist P, Sarndahl E. Gene polymorphisms in the NALP3 inflammasome are associated with interleukin-1 production and severe inflammation: relation to common inflammatory diseases?. Arthritis Rheum 2008, 58:888-894. 10.1002/art.23286, 18311798.
9. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004, 20:319-325. 10.1016/S1074-7613(04)00046-9, 15030775.
10. Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1β in inflammatory disorders. Nat Clin Pract Rheumatol 2008, 4:34-42. 10.1038/ncprheum0681, 18172447.
11. Jiang Z, Georgel P, Du X, Shamel L, Sovath S, Mudd S, Huber M, Kalis C, Keck S, Galanos C, Freudenberg M, Beutler B. CD14 is required for MyD88-independent LPS signaling. Nat Immunol 2005, 6:565-570. 10.1038/ni1207, 15895089.
12. Herlands RA, Christensen SR, Sweet RA, Hershberg U, Shlomchik MJ. T cell-independent and toll-like receptor-dependent antigen-driven activation of autoreactive B cells. Immunity 2008, 29:249-260. 10.1016/j.immuni.2008.06.009, 18691914.
13. Ganley-Leal LM, Liu X, Wetzler LM. Toll-like receptor 2-mediated human B cell differentiation. Clin Immunol 2006, 120:272-284. 10.1016/j.clim.2006.04.571, 16766226.
14. Heijden IM, Wilbrink B, Tchetverikov I, Schrijver IA, Schouls LM, Hazenberg MP, Breedveld FC, Tak PP. Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides. Arthritis Rheum 2000, 43:593-598. 10.1002/1529-0131(200003)43:3<593::AID-ANR16>3.0.CO;2-1, 10728753.
15. Blaschke S, Schwarz G, Moneke D, Binder L, Muller G, Reuss-Borst M. Epstein-Barr virus infection in peripheral blood mononuclear cells, synovial fluid cells, and synovial membranes of patients with rheumatoid arthritis. J Rheumatol 2000, 27:866-873.
16. Ospelt C, Brentano F, Rengel Y, Stanczyk J, Kolling C, Tak PP, Gay RE, Gay S, Kyburz D. Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis. Arthritis Rheum 2008, 58:3684-3692. 10.1002/art.24140, 19035519.
17. Brentano F, Schorr O, Gay RE, Gay S, Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum 2005, 52:2656-2665. 10.1002/art.21273, 16142732.
18. Roelofs MF, Joosten LA, Abdollahi-Roodsaz S, van Lieshout AW, Sprong T, Hoogen FH, Berg WB, Radstake TR. The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum 2005, 52:2313-2322. 10.1002/art.21278, 16052591.
19. Huang Q, Ma Y, Adebayo A, Pope RM. Increased macrophage activation mediated through toll-like receptors in rheumatoid arthritis. Arthritis Rheum 2007, 56:2192-2201. 10.1002/art.22707, 17599732.
20. Sacre SM, Andreakos E, Kiriakidis S, Amjadi P, Lundberg A, Giddins G, Feldmann M, Brennan F, Foxwell BM. The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis. Am J Pathol 2007, 170:518-525. 1851858, 17255320, 10.2353/ajpath.2007.060657.
21. Abdollahi-Roodsaz S, Joosten LA, Roelofs MF, Radstake TR, Matera G, Popa C, Meer JW, Netea MG, Berg WB. Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum 2007, 56:2957-2967. 10.1002/art.22848, 17763416.
22. Abdollahi-Roodsaz S, Joosten LA, Koenders MI, Devesa I, Roelofs MF, Radstake TR, Heuvelmans-Jacobs M, Akira S, Nicklin MJ, Ribeiro-Dias F, Berg WB. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J Clin Invest 2008, 118:205-216. 2104479, 18060042, 10.1172/JCI32639.
23. Joosten LA, Koenders MI, Smeets RL, Heuvelmans-Jacobs M, Helsen MM, Takeda K, Akira S, Lubberts E, Loo FA, Berg WB. Toll-like receptor 2 pathway drives streptococcal cell wall-induced joint inflammation: critical role of myeloid differentiation factor 88. J Immunol 2003, 171:6145-6153.
24. Abdollahi-Roodsaz S, Joosten LA, Helsen MM, Walgreen B, van Lent PL, Bersselaar LA, Koenders MI, Berg WB. from toll-like receptor 2 (TLR-2) toward TLR-4 dependency in the erosive stage of chronic streptococcal cell wall arthritis coincident with TLR-4-mediated interleukin-17 production. Arthritis Rheum 2008, 58:3753-3764. 10.1002/art.24127, 19035506.
25. Goldstein RS, Bruchfeld A, Yang L, Qureshi AR, Gallowitsch-Puerta M, Patel NB, Huston BJ, Chavan S, Rosas-Ballina M, Gregersen PK, Czura CJ, Sloan RP, Sama AE, Tracey KJ. Cholinergic anti-inflammatory pathway activity and high mobility group box-1 (HMGB1) serum levels in patients with rheumatoid arthritis. Mol Med 2007, 13:210-215. 1899837, 17597834, 10.2119/2006-00108.Goldstein.
26. Huang QQ, Sobkoviak R, Jockheck-Clark AR, Shi B, Mandelin AM, Tak PP, Haines GK, Nicchitta CV, Pope RM. Heat shock protein 96 is elevated in rheumatoid arthritis and activates macrophages primarily via TLR2 signaling. J Immunol 2009, 182:4965-4973. 10.4049/jimmunol.0801563, 19342676.
27. Kilding R, Akil M, Till S, Amos R, Winfield J, Iles MM, Wilson AG. A biologically important single nucleotide polymorphism within the toll-like receptor-4 gene is not associated with rheumatoid arthritis. Clin Exp Rheumatol 2003, 21:340-342.
28. Sanchez E, Orozco G, Lopez-Nevot MA, Jimenez-Alonso J, Martin J. Polymorphisms of toll-like receptor 2 and 4 genes in rheumatoid arthritis and systemic lupus erythematosus. Tissue Antigens 2004, 63:54-57. 10.1111/j.1399-0039.2004.00162.x, 14651524.
29. Ospelt C, Brentano F, Jungel A, Rengel Y, Kolling C, Michel BA, Gay RE, Gay S. Expression, regulation, and signaling of the pattern-recognition receptor nucleotide-binding oligomerizastion domain 2 in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2009, 60:355-363. 10.1002/art.24226, 19180502.
30. Joosten LA, Heinhuis B, Abdollahi-Roodsaz S, Ferwerda G, Lebourhis L, Philpott DJ, Nahori MA, Popa C, Morre SA, Meer JW, Girardin SE, Netea MG, Berg WB. Differential function of the NACHT-LRR (NLR) members Nod1 and Nod2 in arthritis. Proc Natl Acad Sci USA 2008, 105:9017-9022. 2449357, 18574154, 10.1073/pnas.0710445105.
31. Hirschfeld M, Kirschning CJ, Schwandner R, Wesche H, Weis JH, Wooten RM, Weis JJ. Cutting edge: inflammatory signaling by Borrelia burgdorferi lipoproteins is mediated by toll-like receptor 2. J Immunol 1999, 163:2382-2386.
32. Alexopoulou L, Thomas V, Schnare M, Lobet Y, Anguita J, Schoen RT, Medzhitov R, Fikrig E, Flavell RA. Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nat Med 2002, 8:878-884.
33. Schroder NW, Diterich I, Zinke A, Eckert J, Draing C, von Baehr V, Hassler D, Priem S, Hahn K, Michelsen KS, Hartung T, Burmester GR, Gobel UB, Hermann C, Schumann RR. Heterozygous Arg753Gln polymorphism of human TLR-2 impairs immune activation by Borrelia burgdorferi and protects from late stage Lyme disease. J Immunol 2005, 175:2534-2540.
34. Gota C, Calabrese L. Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity 2003, 36:511-518. 10.1080/08916930310001605873, 14984028.
35. Ronnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med 1990, 227:207-210. 10.1111/j.1365-2796.1990.tb00144.x, 1690258.
36. Anders HJ, Vielhauer V, Eis V, Linde Y, Kretzler M, Perez de Lema G, Strutz F, Bauer S, Rutz M, Wagner H, Grone HJ, Schlondorff D. Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J 2004, 18:534-536.
37. Ramos-Casals M, Cuadrado MJ, Alba P, Sanna G, Brito-Zeron P, Bertolaccini L, Babini A, Moreno A, D'Cruz D, Khamashta MA. Acute viral infections in patients with systemic lupus erythematosus: description of 23 cases and review of the literature. Medicine (Baltimore) 2008, 87:311-318. 10.1097/MD.0b013e31818ec711, 19011502.
38. Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, Chang B, Duramad O, Coffman RL. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005, 202:1131-1139. 2213213, 16230478, 10.1084/jem.20050914.
39. Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffman RL. Treatment of lupusprone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 2007, 37:3582-3586. 10.1002/eji.200737815, 18034431.
40. Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, Mamula MJ, Christensen SR, Shlomchik MJ, Viglianti GA, Rifkin IR, Marshak-Rothstein A. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 2005, 202:1171-1177. 2213226, 16260486, 10.1084/jem.20050630.
41. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoanti-body specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006, 25:417-428. 10.1016/j.immuni.2006.07.013, 16973389.
42. Barrat FJ, Coffman RL. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol Rev 2008, 223:271-283. 10.1111/j.1600-065X.2008.00630.x, 18613842.
43. De Jager PL, Richardson A, Vyse TJ, Rioux JD. Genetic variation in toll-like receptor 9 and susceptibility to systemic lupus erythematosus. Arthritis Rheum 2006, 54:1279-1282. 10.1002/art.21755, 16575840.
44. Hur JW, Shin HD, Park BL, Kim LH, Kim SY, Bae SC. Association study of Toll-like receptor 9 gene polymorphism in Korean patients with systemic lupus erythematosus. Tissue Antigens 2005, 65:266-270. 10.1111/j.1399-0039.2005.00374.x, 15730519.
45. Ng MW, Lau CS, Chan TM, Wong WH, Lau YL. Polymorphisms of the toll-like receptor 9 (TLR9) gene with systemic lupus erythematosus in Chinese. Rheumatology (Oxford) 2005, 44:1456-1457. 10.1093/rheumatology/kei120, 16188944.
46. Tao K, Fujii M, Tsukumo S, Maekawa Y, Kishihara K, Kimoto Y, Horiuchi T, Hisaeda H, Akira S, Kagami S, Yasutomo K. Genetic variations of Toll-like receptor 9 predispose to systemic lupus erythematosus in Japanese population. Ann Rheum Dis 2007, 66:905-909. 10.1136/ard.2006.065961, 17344245.
47. Castiblanco J, Varela DC, Castano-Rodriguez N, Rojas-Villarraga A, Hincapie ME, Anaya JM. TIRAP (MAL) S180L polymorphism is a common protective factor against developing tuberculosis and systemic lupus erythematosus. Infect Genet Evol 2008, 8:541-544. 10.1016/j.meegid.2008.03.001, 18417424.
48. Khor CC, Chapman SJ, Vannberg FO, Dunne A, Murphy C, Ling EY, Frodsham AJ, Walley AJ, Kyrieleis O, Khan A, Aucan C, Segal S, Moore CE, Knox K, Campbell SJ, Lienhardt C, Scott A, Aaby P, Sow OY, Grignani RT, Sillah J, Sirugo G, Peshu N, Williams TN, Maitland K, Davies RJ, Kwiatkowski DP, Day NP, Yala D, Crook DW, Marsh K, Berkley JA, O'Neill LA, Hill AV. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 2007, 39:523-528. 2660299, 17322885, 10.1038/ng1976.
49. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, Hua J, An LL, Audoly L, La Rosa G, Bierhaus A, Naworth P, Marshak-Rothstein A, Crow MK, Fitzgerald KA, Latz E, Kiener PA, Coyle AJ. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007, 8:487-496. 10.1038/ni1457, 17417641.
50. Urbonaviciute V, Furnrohr BG, Meister S, Munoz L, Heyder P, De Marchis F, Bianchi ME, Kirschning C, Wagner H, Manfredi AA, Kalden JR, Schett G, Rovere-Querini P, Herrmann M, Voll RE. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med 2008, 205:3007-3018. 2605236, 19064698, 10.1084/jem.20081165.
51. Fernandes-Alnemri T, Yu JW, Datta P, Wu J, Alnemri ES. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 2009, 458:509-513. 10.1038/nature07710, 19158676.
52. Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey DR, Latz E, Fitzgerald KA. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009, 458:514-518. 2726264, 19158675, 10.1038/nature07725.
53. Burckstummer T, Baumann C, Bluml S, Dixit E, Durnberger G, Jahn H, Planyavsky M, Bilban M, Colinge J, Bennett KL, Superti-Furga G. An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol 2009, 10:266-272. 10.1038/ni.1702, 19158679.
54. Kawane K, Ohtani M, Miwa K, Kizawa T, Kanbara Y, Yoshioka Y, Yoshikawa H, Nagata S. Chronic polyarthritis caused by mammalian DNA that escapes from degradation in macrophages. Nature 2006, 443:998-1002. 10.1038/nature05245, 17066036.
55. Raffeiner B, Dejaco C, Duftner C, Kullich W, Goldberger C, Vega SC, Keller M, Grubeck-Loebenstein B, Schirmer M. Between adaptive and innate immunity: TLR4-mediated perforin production by CD28null T-helper cells in ankylosing spondylitis. Arthritis Res Ther 2005, 7:R1412-R1420. 1297589, 16277694, 10.1186/ar1840.
56. Snelgrove T, Lim S, Greenwood C, Peddle L, Hamilton S, Inman R, Rahman P. Association of toll-like receptor 4 variants and ankylosing spondylitis: a case-control study. J Rheumatol 2007, 34:368-370.
57. Paardt M, Crusius JB, de Koning MH, Morre SA, Stadt RJ, Dijkmans BA, Pena AS, Horst-Bruinsma IE. No evidence for involvement of the Toll-like receptor 4 (TLR4) A896G and CD14-C260T polymorphisms in susceptibility to ankylosing spondylitis. Ann Rheum Dis 2005, 64:235-238. 1755347, 15647432, 10.1136/ard.2004.021105.
58. Cantaert T, Stone MA, ter Borg M, Mogg R, De Vries N, Wilson AG, Tak PP, Baeten D. A functional polymorphism of TIR-domain-containing adaptor protein is not associated with axial spondyloarthritis. Ann Rheum Dis 2008, 67:720-722. 10.1136/ard.2007.082784, 18073264.
59. Candia L, Marquez J, Hernandez C, Zea AH, Espinoza LR. Toll-like receptor-2 expression is upregulated in antigen-presenting cells from patients with psoriatic arthritis: a pathogenic role for innate immunity?. J Rheumatol 2007, 34:374-379.
60. So A. Developments in the scientific and clinical understanding of gout. Arthritis Res Ther 2008, 10:221. 2592794, 18947374, 10.1186/ar2509.
61. Webb R, Jeffries M, Sawalha AH. Uric acid directly promotes human T-cell activation. Am J Med Sci 2009, 337:23-27. 10.1097/MAJ.0b013e31817727af, 19057377.
62. Scott P, Ma H, Viriyakosol S, Terkeltaub R, Liu-Bryan R. Engagement of CD14 mediates the inflammatory potential of monosodium urate crystals. J Immunol 2006, 177:6370-6378.
63. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241. 10.1038/nature04516, 16407889.
64. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007, 9:R28. 1906806, 17352828, 10.1186/ar2143.
65. McGonagle D, Tan AL, Madden J, Emery P, McDermott MF. Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum 2008, 58:631-633. 10.1002/art.23119, 18240249.
66. Scanzello CR, Plaas A, Crow MK. Innate immune system activation in osteoarthritis: is osteoarthritis a chronic wound?. Curr Opin Rheumatol 2008, 20:565-572. 10.1097/BOR.0b013e32830aba34, 18698179.
67. Zhang Q, Hui W, Litherland GJ, Barter MJ, Davidson R, Darrah C, Donell ST, Clark IM, Cawston TE, Robinson JH, Rowan AD, Young DA. Differential Toll-like receptor-dependent collagenase expression in chondrocytes. Ann Rheum Dis 2008, 67:1633-1641. 10.1136/ard.2007.079574, 18258708.
68. Su SL, Tsai CD, Lee CH, Salter DM, Lee HS. Expression and regulation of Toll-like receptor 2 by IL-1β and fibronectin fragments in human articular chondrocytes. Osteoarthritis Cartilage 2005, 13:879-886. 10.1016/j.joca.2005.04.017, 15961329.
69. Kim HA, Cho ML, Choi HY, Yoon CS, Jhun JY, Oh HJ, Kim HY. The catabolic pathway mediated by Toll-like receptors in human osteoarthritic chondrocytes. Arthritis Rheum 2006, 54:2152-2163. 10.1002/art.21951, 16802353.
70. Whelan LC, Morgan MP, McCarthy GM. Basic calcium phosphate crystals as a unique therapeutic target in osteoarthritis. Front Biosci 2005, 10:530-541. 10.2741/1549, 15574390.
71. Pay S, Terkeltaub R. Calcium pyrophosphate dihydrate and hydroxyapatite crystal deposition in the joint: new developments relevant to the clinician. Curr Rheumatol Rep 2003, 5:235-243. 10.1007/s11926-003-0073-x, 12744817.
72. Oliviero F, Frallonardo P, Peruzzo L, Ramonda R, Sfriso P, Scanu A, Tauro L, Liote F, Punzi L. Evidence of silicon dioxide crystals in synovial fluid of patients with osteoarthritis. J Rheumatol 2008, 35:1092-1095.
73. Ea HK, Liote F. Advances in understanding calcium-containing crystal disease. Curr Opin Rheumatol 2009, 21:150-157. 10.1097/BOR.0b013e3283257ba9, 19339926.
74. Caicedo MS, Desai R, McAllister K, Reddy A, Jacobs JJ, Hallab NJ. Soluble and particulate Co-Cr-Mo alloy implant metals activate the inflammasome danger signaling pathway in human macrophages: a novel mechanism for implant debris reactivity. J Orthop Res 2008, 27:847-854. 19105226, 10.1002/jor.20826.